https://www.astrazeneca.ru/content/az-ru/media/news/2020/20201211-ru201.html

Today we announce a clinical trial programme to assess safety and immunogenicity of combination of AZD1222, developed by AstraZeneca and Oxford University and Sputnik V, developed by Russian Gamaleya Research institute. It will begin enrolling adults aged 18 years and older.